Cambridge Healthtech Institute’s 2nd Annual

Constrained Peptides and Macrocyclics
( 拘束性肽及大环状肽 )


As the drug discovery industry starts to exhaust the types of molecules (small molecules and biologics) that have drug potential, it is moving towards investigation of ‘middle-sized’ molecules that cover ‘new drug space.’ These constrained peptides and synthetic macrocyclic molecules are attractive in theory because they should be small enough to enter cells and reach intracellular drug targets, thus expanding the types of targets available to larger protein biologics and having the potential to be developed as oral-based therapies. Yet they should be big enough to engage in more specific interactions, thereby reducing potential off-target side effects and being able to better disrupt protein-complexes, a new type of drug target also known as protein-protein interaction (PPI) targets. Join colleagues at CHI’s Constrained Peptides and Macrocyclics conference to discuss the design strategies and challenges in screening for and optimizing this new class of drug compounds.


Who should attend: Immunologists, Discovery Biologists, Discovery Chemists from academic and pharmaceutical departments such as inflammation, immunology, autoimmune diseases, fibrosis, infectious diseases, molecular pharmacology, cardiometabolic diseases, and molecular pharmacology


Coverage will include, but is not limited to:                                        

  • DNA-encoded or template-based macrocyclic or constrained peptide libraries
  • Synthetic macrocyclic challenges
  • Peptide cyclization strategies
  • Drug design lessons from natural products
  • Designing for cell permeability and solubility: Beyond Lipinski’s Rule of Five (BRo5)
  • Challenges in screening for macrocyclics
  • Synthetic macrocyclic or constrained peptide drug leads and candidates


* 活动内容有可能不事先告知作更动及调整。

Choose your language